TrumpRx, AstraZeneca, Sanofi, mRNA: Pharma Readout Newsletter
News Context
At a glance
- Former President Donald Trump's promised discount drug program, TrumpRx, faces continued delays, and Sanofi is scaling back its efforts to develop an mRNA-based flu vaccine.
Former President Donald Trump’s promised discount drug program, TrumpRx, faces continued delays, and Sanofi is scaling back its efforts to develop an mRNA-based flu vaccine.
The need-to-know this morning
- Regeneron Pharmaceuticals anticipates an FDA decision in the first half of 2026 regarding its gene therapy, DB-OTO, for a rare genetic form of hearing loss.The company filed its application in December and received a Commissioner’s national Priority Voucher in October. Regeneron also recently released its fourth-quarter and full-year 2025 financial results. More details are available here.
- European regulators have launched a review of Amgen‘s drug Tavneos after concerns arose about the integrity of data from a key study supporting its approval.Tavneos treats severe inflammatory conditions affecting blood vessels. Read the EMA announcement.
- Moderna announced that Chief Medical Officer Jaqueline Miller is leaving the company. The reason for her departure wasn’t disclosed. David Berman has been appointed as the new chief progress officer. Find the full press release here.